UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On November 28, 2022, CinCor Pharma, Inc. (the “Company”) issued a press release announcing the topline results and completion of its Phase 2 HALO trial evaluating the efficacy and safety of its lead clinical candidate, baxdrostat, in patients with uncontrolled hypertension taking up to two blood pressure medications at the maximally tolerated doses. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
The Company will host a conference call and webcast in connection with the above-referenced announcement at 8:00 a.m., Eastern Time, on November 28, 2022. A live audio webcast of the presentation will be available under “Events and Presentations” in the “Investors” section of the Company’s website at www.cincor.com. The webcast will be archived on the Company’s website for at least 30 days following the call. Details regarding the conference call and webcast can be found in the press release. The corporate presentation regarding the Phase 2 HALO trial results that the Company will be presenting on the conference call and webcast will be made available under “Events and Presentations” in the “Investors” section of the Company’s website at www.cincor.com.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. The Company’s website and the information contained on, or that can be accessed through, the Company’s website will not be deemed to be incorporated by reference in, and are not considered part of, this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
|
Description |
99.1 |
|
Press Release issued by CinCor Pharma, Inc., dated November 28, 2022 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Cincor Pharma, Inc. |
|
|
|
|
Date: |
November 28, 2022 |
By: |
/s/ Michael W. Kalb |
|
|
|
Michael W. Kalb, Executive Vice President and Chief Financial Officer |